-J&J -FDA Approves XARELTO (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation; XARELTO Combines Proven Effectiveness and Demonstrated Safety Profile with Convenient, Once-Daily Dosing - ENP Newswire

-J&J -FDA Approves XARELTO (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation; XARELTO Combines Proven Effectiveness and Demonstrated Safety Profile with Convenient, Once-Daily Dosing

von ENP Newswire

  • Veröffentlichungsdatum: 2011-11-07
  • Genre: Business und Finanzen

Beschreibung

ENPNewswire-November 7, 2011--J&J -FDA Approves XARELTO (Rivaroxaban) To Reduce The Risk Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation; XARELTO Combines Proven Effectiveness And Demonstrated Safety Profile With Convenient, Once-Daily Dosing(C)2011 ENPublishing - http://www.enpublishing.co.uk ENP Newswire - 07 November 2011

Impressum und Kontakt

Software © by Hi Web Wiesbaden
Alle Rechte vorbehalten